Insider Transactions in Q1 2023 at Ocular Therapeutix, Inc (OCUL)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2023
|
Christopher G White Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,829
-5.79%
|
$23,316
$4.24 P/Share
|
|
Feb 06
2023
|
Antony C. Mattessich President and CEO |
SELL
Open market or private sale
|
Direct |
19,669
-4.22%
|
$78,676
$4.24 P/Share
|
|
Feb 06
2023
|
Philip C. Strassburger General Counsel |
SELL
Open market or private sale
|
Direct |
6,181
-5.36%
|
$24,724
$4.24 P/Share
|
|
Feb 06
2023
|
Donald Notman Officer |
SELL
Open market or private sale
|
Direct |
6,476
-4.44%
|
$25,904
$4.24 P/Share
|
|
Feb 06
2023
|
Rabia Gurses Ozden Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,416
-5.95%
|
$25,664
$4.24 P/Share
|
|
Jan 30
2023
|
Philip C. Strassburger General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
55,556
+32.53%
|
-
|
|
Jan 30
2023
|
Christopher G White Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,444
+30.64%
|
-
|
|
Jan 30
2023
|
Antony C. Mattessich President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
176,300
+27.45%
|
-
|
|
Jan 30
2023
|
Donald Notman Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,556
+27.58%
|
-
|
|
Jan 30
2023
|
Rabia Gurses Ozden Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,556
+34.01%
|
-
|